What is Pherecydes Pharma?
Pherecydes Pharma is a biotechnology company focused on developing innovative therapeutic solutions. While the provided description is generic and appears to be for a different entity (Sydney Lotto), Pherecydes Pharma's funding trajectory, particularly its Series B round, suggests a company scaling its operations and advancing its pipeline. The company's strategic capital raises indicate a focus on research and development, clinical trials, and potential market entry for its proprietary technologies. The enterprise-level funding signifies strong investor confidence in its long-term vision and the potential impact of its scientific advancements.
How much funding has Pherecydes Pharma raised?
Pherecydes Pharma has raised a total of $15.5M across 3 funding rounds:
Series A
$2.3M
Unspecified
$2.9M
Series B
$10.3M
Series A (2014): $2.3M with participation from Auriga Partners
Unspecified (2015): $2.9M, investors not publicly disclosed
Series B (2018): $10.3M supported by Auriga Partners, Omnes Capital, Go Capital, and Fa-Dièse
Key Investors in Pherecydes Pharma
Auriga Partners
Auriga Partners is a venture capital firm that likely focuses on providing growth capital to companies in sectors with high innovation potential, such as biotechnology.
Omnes Capital
Omnes Capital is a European private equity firm with a strong focus on the energy transition and deeptech innovation, suggesting they may invest in companies with transformative technological platforms.
Go Capital
GEOC (Go Capital) is a China-Israel fund that invests in Israeli high-tech companies, particularly in Life Sciences, and assists them in penetrating the Chinese market, indicating a strategic interest in global expansion and cross-border collaboration.
What's next for Pherecydes Pharma?
With a recent major strategic investment and a history of significant capital raises, Pherecydes Pharma is poised for accelerated growth. The company is likely to leverage this financing to advance its drug development programs, expand its research capabilities, and potentially pursue strategic partnerships or acquisitions. The focus on enterprise-level funding suggests a move towards later-stage development or commercialization efforts. Investors will be closely watching Pherecydes Pharma's progress in clinical trials and its ability to translate scientific innovation into tangible therapeutic solutions, further solidifying its position in the biopharmaceutical sector.
See full Pherecydes Pharma company page
